This site is intended for U.S. healthcare professionals. It may include information about investigational drug products or uses that have not been approved by the US Food and Drug Administration (FDA) and/or other health authorities. These presentations are being shared in the interest of scientific exchange and in transparency of Aquestive Therapeutic's innovative research activities to healthcare professionals.
Novel Sublingual Epinephrine Is Not Associated With a Diastolic Blood Pressure Dip
Pharmacokinetics/Pharmacodynamics
Sublingual epinephrine administration was not associated with the transient decrease in diastolic blood pressure often observed with intramuscular epinephrine.
Gary Slatko MD; David Golden MD; Nils F. Confer, PhD; Elisabeth Kilroy PhD; Matthew Greenhawt MD, MBA, MSc
Epinephrine Plasma Concentration and Hemodynamic Threshold Response Following Sublingual Epinephrine Administration
Pharmacokinetics/Pharmacodynamics
An analysis of plasma epinephrine exposure and cardiovascular responses in healthy adults
Matthew Greenhawt MD, MBA, MSc; David GoldenMD; Nils F. Confer PhD; Elisabeth Kilroy PhD; Gary Slatko MD
Sublingual epinephrine (Anaphylm™) provides consistent pharmacokinetics in both adult and pediatric subjects
Pharmacokinetics/Pharmacodynamics
Presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting
Nils F. Confer, PhD, Matthew Greenhawt, MD, David Golden, MD, Aikaterini Anagnostou, MD, Carl N. Kraus, MD
Recognizing unmet needs in anaphylaxis care: Insights from clinician and caregiver surveys
Survey Data
Presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting
Nils F. Confer, PhD, Carl N. Kraus, MD
Phase 1 evaluation of Anaphylm™ sublingual film: Pharmacokinetics, pharmacodynamics, safety, and tolerability in pediatric patients at high risk for allergic reactions
Pharmacokinetics/Pharmacodynamics
Presented at the 2025 American Academy of Pediatrics National Conference & Exhibition
Nils F. Confer, PhD, Matthew Greenhawt, MD, Douglas P. Mack, MD, Shazad Mustafa, MD, H. Henry Li, MD, PhD, Carl N. Kraus, MD
Epinephrine delivered via sublingual film elicits rapid and consistent pharmacokinetic and pharmacodynamic responses
Pharmacokinetics/Pharmacodynamics
Presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2025 Annual Meeting
Carl Kraus, MD, Stephen Wargacki, PhD, David Golden, MD, David Bernstein, MD, Matthew Greenhawt, MD
Durability of epinephrine sublingual film under real-world use
Durability/Stability Results
Presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2025 Annual Meeting
Steve Wargacki, PhD, Vincent Buono, Gregory Tsodikov, Nils Confer, PhD
Stability results of epinephrine sublingual film under extreme temperature conditions
Durability/Stability Results
Presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2025 Annual Meeting
Steve Wargacki, PhD, Vincent Buono, Gregory Tsodikov, Stephanie Varjan
Oral Anaphylm™ Symptom Intervention Study (OASIS)
Pharmacokinetics/Pharmacodynamics
Presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2025 Annual Meeting
Carl Kraus, MD, Stephen Wargacki, PhD, Shawn Berg, Elisabeth Kilroy, PhD
Integrated phase 1 pharmacokinetics and pharmacodynamics of epinephrine administered through sublingual film, autoinjector, or manual injection
Pharmacokinetics/Pharmacodynamics
Published in Annals of Allergy, Asthma & Immunology 2025
Carl N. Kraus, MD, Steve Wargacki, PhD, David Golden, MD, Jay Lieberman, MD, Matthew Greenhawt, MD, MBA, MSc, Carlos A. Camargo, Jr, MD, DrPH
Impact of food exposure on the pharmacokinetics of epinephrine sublingual film
Pharmacokinetics/Pharmacodynamics
Presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2023 Annual Meeting
John Oppenheimer, MD, David Golden, MD, Carlos A. Camargo, Jr, MD, DrPH, Matthew Greenhawt, MD, MBA, MSc, David Fleisher, MD, David Bernstein, MD, Gary Slatko, MD